Sequenom Announces Exclusive Licensing Agreement with Xenomics for Noninvasive Prenatal Diagnostics Using Transrenal DNA
News Oct 30, 2008
"Sequenom's significant position in noninvasive prenatal diagnostics is further enhanced by these patent rights," stated Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "Use of transrenal fetal DNA in maternal urine is an innovative approach to prenatal diagnostics that we believe has compelling future commercial potential. We are continuing to evaluate strategic opportunities to broaden and deepen our IP position as we expand our SEQureDx(TM) franchise into new areas of prenatal diagnostics and build a long-term leadership position for Sequenom in this growth market."
The license provides Sequenom with exclusive global rights to use transrenal fetal nucleic acids in maternal urine for noninvasive prenatal diagnostics and analysis on a technology-independent basis for all uses, excluding fetal gender determination solely by the presence of Y chromosome. The exclusive rights extend the SEQureDx prenatal diagnostic technology franchise that the Company is building by enabling the development of products for, and the protection of, an additional source of novel, noninvasive fetal sample and testing.
Sequenom's Proprietary Noninvasive Prenatal Diagnostics Sequenom's commercial opportunities in prenatal diagnostics are built upon its SEQureDx technology and are enabled by the pioneering inventions and associated intellectual property rights that it has exclusively licensed from Isis Innovation Ltd., the technology transfer company of the University of Oxford, as well as The Chinese University of Hong Kong. Sequenom's portfolio of noninvasive prenatal
diagnostic patent rights and patent applications is platform-independent, includes genetic-analysis methods using circulating cell-free fetal nucleic acids from maternal samples, and also includes a portfolio of methylation and nucleic-acid markers.
Sequenom is actively expanding its intellectual property position with new technology and new territories. Because Sequenom's license rights are platform-independent, the rights provide exclusivity (with the narrow exception in Europe for RT-PCR-based Rhesus D tests) for development and commercialization of noninvasive prenatal tests on any platform and are not limited to the Company's MassARRAY(R) platform.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE